Back to results
US 2007/0178504 A1Published application
Methods and marker combinations for screening for predisposition to lung cancer
OwnerTracey Colpitts, Eric Russell +4inventors
InventorsTracey Colpitts, Eric Russell, Stephen Frost, Javier Ramirez, Bhawani Singh, John Russell
Life of this patent
Estimating the term…
Abstract
The present invention relates to certain immunoreactive polypeptides, methods for aiding in the diagnosis of lung cancer in a subject and kits for performing said methods.
Claims73
A method of aiding in a diagnosis of a subject suspected of lung cancer, the method comprising the steps of:
- a. obtaining a test sample from a subject;
- b. quantifying in the test sample the amount of one or more biomarkers in a panel;
- c. comparing the amount of each biomarker in the panel to a predetermined cutoff for said biomarker and assigning a score for each biomarker based on said comparison;
- d. combining the assigned score for each biomarker determined in step c to come up with a total score for said subject;
- e. comparing the total score determined in step d with a predetermined total score;
- and
- f. determining whether said subject has a risk of lung cancer based on the total score.
4 more elements
A method of aiding in a diagnosis of a subject suspected of lung cancer, the method comprising the steps of:
- a. obtaining at least one biometric parameter of a subject;
- b. comparing the at least one biometric parameter against a predetermined cutoff for each said biometric parameter and assigning a score for each biometric parameter based on said comparison;
- c. obtaining a test sample from a subject;
- d. quantifying in the test sample the amount of two or more biomarkers in a panel, the panel comprising at least one antibody and at least one antigen;
- e. comparing the amount of each biomarker quantified in the panel to a predetermined cutoff for said biomarker and assigning a score for each biomarker based on said comparison;
- f. combining the assigned score for each biometric parameter determined in step b with the assigned score for each biomarker quantified in step e to come up with a total score for said subject;
- g. comparing the total score determined in step f with a predetermined total score;
- and
- h. determining whether said subject has a risk of lung cancer based on the total score determined in step f.
6 more elements
A method of aiding in a diagnosis of a subject suspected of lung cancer, the method comprising the steps of:
- a. obtaining a test sample from a subject;
- b. quantifying in the test sample the amount of two or more biomarkers in a panel, the panel comprising at least one antibody and at least one antigen;
- c. comparing the amount of each biomarker quantified in the panel to a predetermined cutoff for said biomarker and assigning a score for each biomarker based on said comparison;
- d. combining the assigned score for each biomarker quantified in step c to come up with a total score for said subject;
- e. comparing the total score determined in step d with a predetermined total score;
- and
- f. determining whether said subject has a risk of lung cancer based on the total score determined in step e.
4 more elements
A method of aiding in a diagnosis of subject suspected of lung cancer, the method comprising the steps of:
- a. obtaining a test sample from a subject;
- b. quantifying in the test sample an amount of at least one biomarker in a panel, the panel comprising at least one antibody against immunoreactive Cyclin E2;
- c. comparing the amount of each biomarker quantified in the panel to a predetermined cutoff for said biomarker and assigning a score for each biomarker based on said comparison;
- d. combining the assigned score for each biomarker quantified in step c to come up with a total score for said subject;
- e. comparing the total score determined in step d with a predetermined total score;
- and
- f. determining whether said subject has lung cancer based on the total score determined in step e.
4 more elements
A method of aiding in a diagnosis of subject suspected of lung cancer, the method comprising the steps of:
- a. obtaining a test sample from a subject;
- b. quantifying in the test sample at least one biomarker in a panel, the panel comprising at least one biomarker selected from the group consisting of:
- cytokeratin 8, cytokeratin 19, cytokeratin 18, CEA, CA125, CA15-3, SCC, CA19-9, proGRP, serum amyloid A, alpha-1-anti-trypsin and apolipoprotein CIII;
- c. comparing the amount of each biomarker quantified in the panel to a predetermined cutoff for said biomarker and assigning a score for each biomarker based on said comparison;
- d. combining the assigned score for each biomarker quantified in step c to come up with a total score for said subject;
- e. comparing the total score quantified in step d with a predetermined total score;
- and
- f. determining whether said subject has lung cancer based on the total score.
5 more elements
A method of aiding in a diagnosis of subject suspected of lung cancer, the method comprising the steps of:
- a. obtaining a test sample from a subject;
- b. quantifying in the test sample at least one biomarker in a panel, the panel comprising at least one biomarker, wherein the biomarker is a region of interest selected from the group consisting of:
- Acn6399, Acn9459, Pub11597, Pub4789, TFA2759, TFA9133, Pub3743, Pub8606, Pub4487, Pub4861, Pub6798, Pub6453, Pub2951, Pub2433, Pub17338, TFA6453 and HIC3959;
- c. comparing the amount of each biomarker quantified in the panel to a predetermined cutoff for said biomarker and assigning a score for each biomarker based on said comparison;
- d. combining the assigned score for each biomarker quantified in step c to come up with a total score for said subject;
- e. comparing the total score quantified in step d with a predetermined total score;
- and
- f. determining whether said subject has lung cancer based on the total score determined in step e.
5 more elements
A method of aiding in a diagnosis of subject suspected of lung cancer, the method comprising the steps of:
- a. obtaining a test sample from a subject;
- b. quantifying in the test sample the amount of two or more biomarkers in a panel, the panel comprising two or more of:
- cytokeratin 19, cytokeratin 18, CA19-9, CEA, CA15-3, CA125, SCC, ProGRP, ACN9459, Pub11597, Pub4789, TFA2759, TFA9133, Pub3743, Pub8606, Pub4487, Pub4861, Pub6798, Tfa6453 and Hic3959;
- c. comparing the amount of each biomarker in the panel to a predetermined cutoff for said biomarker and assigning a score for reach biomarker based on said comparison;
- d. combining the assigned score for each biomarker determined in step c to come up with a total score for said subject;
- e. comparing the total score determined in step d with a predetermined total score;
- and
- f. determining whether said subject has lung cancer based on the total score determined in step e.
5 more elements
A kit comprising:
- a peptide selected from the group consisting of:
- SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or combinations thereof.
A kit comprising:
- at least one antibody against immunoreactive Cyclin E2.
A kit comprising:
- a. reagents containing at least one antibody for quantifying one or more antigens in a test sample, wherein said antigens are:
- cytokeratin 8, cytokeratin 19, cytokeratin 18, CEA, CA125, CA15-3, SCC, CA19-9, proGRP, serum amyloid A, alpha-1-anti-trypsin and apolipoprotein CIII;
- b. reagents containing one or more antigens for quantifying at least one antibody in a test sample;
- wherein said antibodies are:
- anti-p53, anti-TMP21, anti-NPC1L1C-domain, anti-TMOD1, anti-CAMK1, anti-RGS1, anti-PACSIN1, anti-RCV1, anti-MAPKAPK3 and at least one antibody against immunoreactive Cyclin E2;
- c. reagents for quantifying one or more regions of interest selected from the group consisting of:
- ACN9459, Pub11597, Pub4789, TFA2759, TFA9133, Pub3743, Pub8606, Pub4487, Pub4861, Pub6798, Tfa6453 and Hic3959;
- and
- d. algorithms for combining and comparing the amount of each antigen, antibody and region of interest quantified in the test sample against a predetermined cutoff and assigning a score for each antigen, antibody and region of interest quantified based on said comparison, combining the assigned score for each antigen, antibody and region of interest quantified to obtain a total score, comparing the total score with a predetermined total score and using said comparison as an aid in determining whether a subject has lung cancer.
6 more elements
A kit comprising:
- a. reagents containing at least one antibody for quantifying one or more antigens in a test sample, wherein said antigens are cytokeratin 19, cytokeratin 18, CA19-9, CEA, CA15-3, CA125, SCC and ProGRP;
- b. reagents for quantifying one or more regions of interest selected from the group consisting of:
- ACN9459, Pub11597, Pub4789, TFA2759, TFA9133, Pub3743, Pub8606, Pub4487, Pub4861, Pub6798, Tfa6453 and Hic3959;
- and
- c. one or more algorithms for combining and comparing the amount of each antigen and region of interest quantified in the test sample against a predetermined cutoff, assigning a score for each antigen and region of interest quantified based on said comparison, combining the assigned score for each antigen and region of interest quantified to obtain a total score, comparing the total score with a predetermined total score and using said comparison as an aid in determining whether a subject has lung cancer.
2 more elements
A kit comprising:
- a. reagents containing at least one antibody for quantifying one or more antigens in a test sample, wherein said antigens are cytokeratin 19, cytokeratin 18, CA19-9, CEA, CA15-3, CA125, SCC and ProGRP;
- and
- b. one or more algorithms for combining and comparing the amount of each antigen quantified in the test sample against a predetermined cutoff and assigning a score for each antigen quantified based on said comparison, combining the assigned score for each antigen quantified to obtain a total score, comparing the total score with a predetermined total score and using said comparison as an aid in determining whether a subject has lung cancer.
A kit comprising:
- a. reagents for quantifying one or more biomarkers, wherein said biomarkers are regions of interest selected from the group consisting of:
- ACN9459, Pub11597, Pub4789, TFA2759, TFA9133, Pub3743, Pub8606, Pub4487, Pub4861, Pub6798, Tfa6453 and Hic3959;
- and
- b. one or more algorithms for combining and comparing the amount of each biomarker quantified in the test sample against a predetermined cutoff and assigning a score for each biomarker quantified based on said comparison, combining the assigned score for each biomarker quantified to obtain a total score, comparing the total score with a predetermined total score and using said comparison as an aid in determining whether a subject has lung cancer.
1 more element
An isolated polypeptide having an amino acid sequence selected from the group consisting of:
- SEQ ID NO:3 and a polypeptide having 60% homology to the amino acid sequence of SEQ ID NO:3.
An isolated polypeptide having an amino acid sequence selected from the group consisting of:
- SEQ ID NO:4 and a polypeptide having 60% homology to the amino acid sequence of SEQ ID NO:4.
An isolated polypeptide having an amino acid sequence selected from the group consisting of:
- SEQ ID NO:5 and a polypeptide having 60% homology to the amino acid sequence of SEQ ID NO:5.
A method for scoring one or more markers obtained from a subject, the method comprising the steps of:
- a. obtaining at least one marker from a subject;
- b. quantifying the amount of the marker from said subject;
- c. comparing the amount of each marker quantified to a number of predetermined cutoffs for said marker and assigning a score for each marker based on said comparison;
- and
- d. combining the assigned score for each marker quantified in step c to come up with a total score for said subject.
2 more elements
A method for determining a subject's risk of developing a medical condition, the method comprising the steps of:
- a. obtaining at least one marker from a subject;
- b. quantifying the amount of the marker from said subject;
- c. comparing the amount of each marker quantified to a number of predetermined cutoffs for said marker and assigning a score for each marker based on said comparison;
- d. combining the assigned score for each marker quantified in step c to come up with a total score for said subject;
- e. comparing the total score determined in step d with a predetermined total score;
- and
- f. determining whether said subject has a risk of developing a medical condition based on the total score determined in step e.
4 more elements
Dependencies are inferred from the claim text.